Instead, mutant KRAS with up-regulation of the nuclear factor erythroid 2-related factor 2 (NRF2) causes rearrangement of glutamine metabolic pathways in tumor cells (Hamada et al., 2021). The gene discussed is KRAS; the disease is neoplasm.